149 related articles for article (PubMed ID: 15610407)
1. Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease.
Sánchez AR; Rogers RS; Sheridan PJ
J Oral Pathol Med; 2005 Jan; 34(1):53-5. PubMed ID: 15610407
[TBL] [Abstract][Full Text] [Related]
2. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
3. What next after infliximab?
Baidoo L; Lichtenstein GR
Am J Gastroenterol; 2005 Jan; 100(1):80-3. PubMed ID: 15654785
[TBL] [Abstract][Full Text] [Related]
4. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
6. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
[TBL] [Abstract][Full Text] [Related]
7. Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis.
O'Neill ID; Scully C
Oral Dis; 2012 Oct; 18(7):633-8. PubMed ID: 22420719
[TBL] [Abstract][Full Text] [Related]
8. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
9. Treatment-resistant lingual Crohn's disease disappears after infliximab.
Brunner B; Hirschi C; Weimann R; Seibold F
Scand J Gastroenterol; 2005 Oct; 40(10):1255-9. PubMed ID: 16265783
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
11. [Adalimumab therapy in Crohn's disdease].
Baryshnikov EN; Lazebnik LB; Parfenov AI
Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
Papadakis KA; Shaye OA; Vasiliauskas EA; Ippoliti A; Dubinsky MC; Birt J; Paavola J; Lee SK; Price J; Targan SR; Abreu MT
Am J Gastroenterol; 2005 Jan; 100(1):75-9. PubMed ID: 15654784
[TBL] [Abstract][Full Text] [Related]
15. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
Imaeda H; Andoh A; Fujiyama Y
J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
[TBL] [Abstract][Full Text] [Related]
16. Esophageal ulcer of Crohn's disease: disappearance in 1 week with infliximab.
Chiba M; Sugawara T; Tsuda H; Abe T; Tokairin T; Kashima Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1121-2. PubMed ID: 18942761
[No Abstract] [Full Text] [Related]
17. An unusual cutaneous manifestation of Crohn's disease.
Weiser JA; Markowitz DM; Husain S; Grossman ME
Skinmed; 2011; 9(3):196-8. PubMed ID: 21675504
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
20. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
